Year: 2026
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: Infantile hemangiomas (IH) are common benign vascular tumors of infancy that typically undergo gradual spontaneous regression over several years, although a minority require treatment. Propranolol, a non-selective β‑adrenergic antagonist, is the first-line therapy for complicated or high-risk IH, demonstrating both efficacy and a favorable safety profile. MATERIALS AND METHODS: We retrospectively analyzed 37 infants treated with oral propranolol at a single center. Patients were monitored in-hospital during treatment initiation and at regular, outpatient visits. The response was assessed using clinical measurements, ultrasonography, and standardized photographs. RESULTS: Most patients had solitary lesions predominantly located in the head region. Complete regression occurred in 26 patients (70.3%) and partial regression in 11 (29.7%). Treatment duration ranged from 2 to 24 months (mean 10.1 months). Adverse events were rare and mild, including one case of hypoglycemia and one of transient somnolence. CONCLUSION: Oral propranolol is a safe and effective first-line therapy for IH, particularly when initiated early during the proliferative phase.
Source: Acta Medica Academica
Authors: Jelena Roganović, Andrea Kevrić, Ana Đorđević
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7147127122
FWCI:
Cites:
Cited by:
Related to: